Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Neuimmune Biologics Inc
Profile last edited on: 3/21/2023      CAGE: 7S2K2      UEI: LB7KEQJSNKR4

Business Identifier: Precision glycoengineering and delivery of biologics
Year Founded
2017
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1500 Fannie Dorsey Road
Sykesville, MD 21784
   (301) 983-3780
   N/A
   N/A
Location: Single
Congr. District: 03
County: Carroll

Public Profile

Neuimmune Biologics Inc is structured around development of biopharmaceuticals using glycoengineered CHO cell lines designed for the precise production of prophylactic and therapeutic glycoproteins with significant global healthcare market and revenue impact. The company's focus is on developing innovative vaccines and biopharmaceuticals through the precision glycoengineering and delivery of biologics that address important medical and public health needs, enabling research platforms for delivery and biologics.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$274,441
Phase II Dollars
$0
Total Awarded
$274,441

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $274,441
Project Title: Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin
0 1 NIH $300,000
Project Title: Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine

Key People / Management

  Alexander K Andrianov -- Scientific Founder

  Alain Cappeluti

  Kenneth Carter -- Key Advisor

  Thomas R Fuerst -- Scientific Founder & Chairman

  Mark Hankins -- Licensing and Business Strategy

  Stephen Kevin Horrigan

  John Jessup

  Nathan Lewis -- Scientific Founder

Company News

There are no news available.